CAS NO. |
Products Name |
537672-41-6 |
UF010 |
more... |
UF010 is a potent and selective HADC inhibitor with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs. |
|
1015474-32-4 |
CC122 |
more... |
CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
|
1262417-51-5 |
NMS-P118 |
more... |
NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy with an IC50 of 0.04 μM in HeLa cell. |
|
920509-32-6 |
MGL-3196 |
more... |
MGL-3196 is a highly selective thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. |
|
897657-95-3 |
MSX122 |
more... |
MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM). |
|
1624117-53-8 |
XY1 |
more... |
XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), but XY1 is completely inactive. |
|
|
1061318-81-7 |
Debio0932(CUDC-305 ) |
more... |
Debio 0932 ( CUDC-305 ) is a novel heat shock protein 90 (HSP90) inhibitor trong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L) |
|
923032-37-5 |
Refametinib(RDEA119) |
more... |
Refametinib (RDEA119, BAY 86-9766), is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity (IC50=19 nM MEK1; IC50=47 nM MEK2). |
|
|
947914-18-3 |
ML365 |
more... |
ML365 is a novel selective small molecule inhibitor of TASK1(KCNK3) with IC50 of 4 nM(thallium influx fluorescent assay) and 16 nM(automated electrophysiology assay). |
|
1237744-13-6 |
QNZ46 |
more... |
QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively). |
|